UA79231C2 - Method for a discrete substructural analysis and a computer system for realizing the same - Google Patents
Method for a discrete substructural analysis and a computer system for realizing the same Download PDFInfo
- Publication number
- UA79231C2 UA79231C2 UA2003043420A UA2003043420A UA79231C2 UA 79231 C2 UA79231 C2 UA 79231C2 UA 2003043420 A UA2003043420 A UA 2003043420A UA 2003043420 A UA2003043420 A UA 2003043420A UA 79231 C2 UA79231 C2 UA 79231C2
- Authority
- UA
- Ukraine
- Prior art keywords
- chemical
- molecules
- compounds
- fragments
- fragment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 239
- 238000004458 analytical method Methods 0.000 title claims abstract description 78
- 239000000126 substance Substances 0.000 claims abstract description 372
- 239000012634 fragment Substances 0.000 claims abstract description 258
- 230000008569 process Effects 0.000 claims abstract description 88
- 230000000144 pharmacologic effect Effects 0.000 claims abstract description 37
- 238000000137 annealing Methods 0.000 claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims description 308
- 230000000694 effects Effects 0.000 claims description 82
- 238000004364 calculation method Methods 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 230000015572 biosynthetic process Effects 0.000 claims description 20
- 238000003041 virtual screening Methods 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 9
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 229940126601 medicinal product Drugs 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 230000002363 herbicidal effect Effects 0.000 abstract description 4
- 230000000361 pesticidal effect Effects 0.000 abstract description 4
- 230000003197 catalytic effect Effects 0.000 abstract description 3
- 238000007876 drug discovery Methods 0.000 abstract description 2
- 239000003292 glue Substances 0.000 abstract description 2
- 230000006870 function Effects 0.000 description 129
- 230000002401 inhibitory effect Effects 0.000 description 41
- 102000005962 receptors Human genes 0.000 description 41
- 108020003175 receptors Proteins 0.000 description 41
- 239000003112 inhibitor Substances 0.000 description 40
- 239000003446 ligand Substances 0.000 description 34
- 230000000875 corresponding effect Effects 0.000 description 31
- 238000012216 screening Methods 0.000 description 31
- 238000012360 testing method Methods 0.000 description 28
- 108091000080 Phosphotransferase Proteins 0.000 description 25
- 230000004071 biological effect Effects 0.000 description 25
- 102000020233 phosphotransferase Human genes 0.000 description 25
- 238000004422 calculation algorithm Methods 0.000 description 24
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 230000027455 binding Effects 0.000 description 17
- 238000010586 diagram Methods 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- 108091006146 Channels Proteins 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 15
- 108091005804 Peptidases Proteins 0.000 description 14
- 239000004365 Protease Substances 0.000 description 14
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 14
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 11
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000002110 toxicologic effect Effects 0.000 description 11
- 238000013459 approach Methods 0.000 description 10
- -1 but not limited to Chemical class 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 102000004310 Ion Channels Human genes 0.000 description 9
- 108090000862 Ion Channels Proteins 0.000 description 9
- 102000001253 Protein Kinase Human genes 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 239000003596 drug target Substances 0.000 description 9
- 238000013537 high throughput screening Methods 0.000 description 9
- 108060006633 protein kinase Proteins 0.000 description 9
- 108010052164 Sodium Channels Proteins 0.000 description 8
- 102000018674 Sodium Channels Human genes 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 229940126062 Compound A Drugs 0.000 description 7
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 229960003638 dopamine Drugs 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 229940043355 kinase inhibitor Drugs 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 238000002907 substructure search Methods 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 231100000027 toxicology Toxicity 0.000 description 7
- 108010016626 Dipeptides Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000002213 purine nucleotide Substances 0.000 description 6
- 150000003212 purines Chemical class 0.000 description 6
- 229940044601 receptor agonist Drugs 0.000 description 6
- 239000000018 receptor agonist Substances 0.000 description 6
- 229960004441 tyrosine Drugs 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 150000007514 bases Chemical class 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 239000002547 new drug Substances 0.000 description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 238000012795 verification Methods 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000030609 dephosphorylation Effects 0.000 description 4
- 238000007824 enzymatic assay Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 108010085082 sigma receptors Proteins 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 229940102550 Estrogen receptor antagonist Drugs 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 108090000137 Opioid Receptors Proteins 0.000 description 3
- 102000003840 Opioid Receptors Human genes 0.000 description 3
- 102000016978 Orphan receptors Human genes 0.000 description 3
- 108070000031 Orphan receptors Proteins 0.000 description 3
- 101150059448 cdk7 gene Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000000546 chi-square test Methods 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 238000006209 dephosphorylation reaction Methods 0.000 description 3
- 238000009795 derivation Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 3
- 239000002532 enzyme inhibitor Substances 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 108010038795 estrogen receptors Proteins 0.000 description 3
- 239000004009 herbicide Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000012804 iterative process Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000000575 pesticide Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000004850 protein–protein interaction Effects 0.000 description 3
- 102000028828 purine nucleotide binding proteins Human genes 0.000 description 3
- 108091009376 purine nucleotide binding proteins Proteins 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000012916 structural analysis Methods 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 2
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 238000001358 Pearson's chi-squared test Methods 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- 238000004617 QSAR study Methods 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- HPYDSVWYXXKHRD-VIFPVBQESA-N Tyr-Gly Chemical group [O-]C(=O)CNC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 HPYDSVWYXXKHRD-VIFPVBQESA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 229910052729 chemical element Inorganic materials 0.000 description 2
- 231100000481 chemical toxicant Toxicity 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229940126181 ion channel inhibitor Drugs 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000009822 protein phosphorylation Effects 0.000 description 2
- 230000005588 protonation Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 239000003982 sigma receptor ligand Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000563 toxic property Toxicity 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- YFGBQHOOROIVKG-BHDDXSALSA-N (2R)-2-[[(2R)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound C([C@H](C(=O)N[C@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-BHDDXSALSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
- MYLBTCQBKAKUTJ-UHFFFAOYSA-N 7-methyl-6,8-bis(methylsulfanyl)pyrrolo[1,2-a]pyrazine Chemical compound C1=CN=CC2=C(SC)C(C)=C(SC)N21 MYLBTCQBKAKUTJ-UHFFFAOYSA-N 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 description 1
- 102400000242 Dynorphin A(1-17) Human genes 0.000 description 1
- 108010065372 Dynorphins Proteins 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102400000243 Leu-enkephalin Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010022337 Leucine Enkephalin Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100032587 MOB-like protein phocein Human genes 0.000 description 1
- 101710168500 MOB-like protein phocein Proteins 0.000 description 1
- 101150104182 MOB2 gene Proteins 0.000 description 1
- 102400000988 Met-enkephalin Human genes 0.000 description 1
- 108010042237 Methionine Enkephalin Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101100018694 Rattus norvegicus Il24 gene Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- JXASPPWQHFOWPL-UHFFFAOYSA-N Tamarixin Natural products C1=C(O)C(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 JXASPPWQHFOWPL-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 231100000777 Toxicophore Toxicity 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 238000013098 chemical test method Methods 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 102000003898 interleukin-24 Human genes 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 102000026415 nucleotide binding proteins Human genes 0.000 description 1
- 108091014756 nucleotide binding proteins Proteins 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000002263 peptidergic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 238000000547 structure data Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/40—Searching chemical structures or physicochemical data
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biotechnology (AREA)
- Computing Systems (AREA)
- Pharmacology & Pharmacy (AREA)
- Evolutionary Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Complex Calculations (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00309114 | 2000-10-17 | ||
| PCT/EP2001/011955 WO2002033596A2 (en) | 2000-10-17 | 2001-10-16 | Method of operating a computer system to perform a discrete substructural analysis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA79231C2 true UA79231C2 (en) | 2007-06-11 |
Family
ID=8173320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2003043420A UA79231C2 (en) | 2000-10-17 | 2001-10-16 | Method for a discrete substructural analysis and a computer system for realizing the same |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20040083060A1 (xx) |
| EP (1) | EP1366440A2 (xx) |
| JP (2) | JP2004512603A (xx) |
| KR (1) | KR20030059196A (xx) |
| CN (1) | CN1264110C (xx) |
| AU (2) | AU2002215028B2 (xx) |
| BG (1) | BG107717A (xx) |
| BR (1) | BR0114987A (xx) |
| CA (1) | CA2423672A1 (xx) |
| CZ (1) | CZ20031090A3 (xx) |
| EA (1) | EA005286B1 (xx) |
| EE (1) | EE200300150A (xx) |
| HK (1) | HK1061911A1 (xx) |
| HR (1) | HRP20030240A2 (xx) |
| HU (1) | HUP0302507A3 (xx) |
| IL (1) | IL155332A0 (xx) |
| MX (1) | MXPA03003422A (xx) |
| NO (1) | NO20031730D0 (xx) |
| PL (1) | PL364772A1 (xx) |
| SK (1) | SK4682003A3 (xx) |
| UA (1) | UA79231C2 (xx) |
| WO (1) | WO2002033596A2 (xx) |
| YU (1) | YU25603A (xx) |
| ZA (1) | ZA200302395B (xx) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005069188A1 (ja) * | 2003-12-26 | 2005-07-28 | Dainippon Sumitomo Pharma Co., Ltd. | 化合物および蛋白質間の相互作用を予測するシステム |
| CA2554979A1 (en) * | 2004-03-05 | 2005-09-29 | Applied Research Systems Ars Holding N.V. | Method for fast substructure searching in non-enumerated chemical libraries |
| JP2006090733A (ja) * | 2004-09-21 | 2006-04-06 | Fuji Photo Film Co Ltd | 化合物抽出装置およびプログラム |
| EP1762954B1 (en) * | 2005-08-01 | 2019-08-21 | F.Hoffmann-La Roche Ag | Automated generation of multi-dimensional structure activity and structure property relationships |
| JP5512077B2 (ja) * | 2006-11-22 | 2014-06-04 | 株式会社 資生堂 | 安全性評価方法、安全性評価システム及び安全性評価プログラム |
| CN102282560B (zh) * | 2008-12-05 | 2015-08-19 | 狄克雷佩特公司 | 用于产生马库什结构专利权利要求内的虚拟化合物链接库的方法 |
| CN102043864A (zh) * | 2010-12-30 | 2011-05-04 | 中山大学 | 中药心血管毒性分析的计算机操作方法及其系统 |
| EP2698733A4 (en) * | 2011-04-11 | 2014-12-03 | Jingbo Yan | USES OF A MULTIDIMENSIONAL MATRIX IN THE DESIGN OF PHARMACEUTICAL MOLECULES AND METHOD FOR DESIGNING PHARMACEUTICAL MOLECULES |
| CN102262715B (zh) * | 2011-06-01 | 2013-09-11 | 山东大学 | Bcl-2蛋白抑制剂三维定量构效关系模型的构建方法及应用 |
| ES2392915B1 (es) * | 2011-06-03 | 2013-09-13 | Univ Sevilla | Compuestos bioactivos polifenolicos conteniendo azufre o selenio y sus usos |
| WO2014047463A2 (en) * | 2012-09-22 | 2014-03-27 | Bioblocks, Inc. | Libraries of compounds having desired properties and methods for making and using them |
| CN103049674A (zh) * | 2013-01-26 | 2013-04-17 | 北京东方灵盾科技有限公司 | 一种化学药物hERG钾离子通道阻断作用的定性预测方法及其系统 |
| US9799006B2 (en) | 2013-10-08 | 2017-10-24 | Baker Hughes Incorporated | Methods, systems and computer program products for chemical hazard evaluation |
| US9424517B2 (en) | 2013-10-08 | 2016-08-23 | Baker Hughes Incorporated | Methods, systems and computer program products for chemical hazard evaluation |
| WO2016179531A1 (en) * | 2015-05-07 | 2016-11-10 | University Of Kentucky Research Foundation | Method for designing compounds and compositions useful for targeting high stoichiometric complexes to treat conditions |
| EP3206145A1 (en) * | 2016-02-09 | 2017-08-16 | InnovativeHealth Group SL | Method for producing a topical dermal formulation for cosmetic use |
| WO2018220368A1 (en) * | 2017-05-30 | 2018-12-06 | Gtn Ltd | Tensor network machine learning system |
| US11710543B2 (en) | 2017-10-19 | 2023-07-25 | Schrödinger, Inc. | Methods for predicting an active set of compounds having alternative cores, and drug discovery methods involving the same |
| CN113348514B (zh) | 2018-09-13 | 2024-03-08 | 思科利康有限公司 | 预测化学结构性质的方法和系统 |
| CN112689877A (zh) * | 2018-09-14 | 2021-04-20 | 富士胶片株式会社 | 化合物的合成适用性的评价方法、化合物的合成适用性的评价程序及化合物的合成适用性的评价装置 |
| US11580275B1 (en) * | 2018-12-18 | 2023-02-14 | X Development Llc | Experimental discovery processes |
| EP3712897A1 (en) * | 2019-03-22 | 2020-09-23 | Tata Consultancy Services Limited | Automated prediction of biological response of chemical compounds based on chemical information |
| CN110728078B (zh) * | 2019-11-14 | 2022-11-25 | 吉林大学 | 一种基于胶粘剂化学特性的粘接结构在全服役温度区间下的力学性能的预测方法 |
| CN111354424B (zh) * | 2020-02-27 | 2023-06-23 | 北京晶泰科技有限公司 | 一种潜在活性分子的预测方法、装置和计算设备 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994028504A1 (en) * | 1993-05-21 | 1994-12-08 | Arris Pharmaceutical | A machine-learning approach to modeling biological activity for molecular design and to modeling other characteristics |
| US5463564A (en) * | 1994-09-16 | 1995-10-31 | 3-Dimensional Pharmaceuticals, Inc. | System and method of automatically generating chemical compounds with desired properties |
| EP1163613A1 (en) * | 1999-02-19 | 2001-12-19 | Bioreason, Inc. | Method and system for artificial intelligence directed lead discovery through multi-domain clustering |
| AU4565600A (en) * | 1999-06-18 | 2001-01-09 | Synt:Em (S.A.) | Identifying active molecules using physico-chemical parameters |
-
2001
- 2001-10-16 ZA ZA200302395A patent/ZA200302395B/en unknown
- 2001-10-16 HU HU0302507A patent/HUP0302507A3/hu unknown
- 2001-10-16 EA EA200300475A patent/EA005286B1/ru not_active IP Right Cessation
- 2001-10-16 AU AU2002215028A patent/AU2002215028B2/en not_active Ceased
- 2001-10-16 EE EEP200300150A patent/EE200300150A/xx unknown
- 2001-10-16 KR KR10-2003-7005331A patent/KR20030059196A/ko not_active Application Discontinuation
- 2001-10-16 US US10/399,329 patent/US20040083060A1/en not_active Abandoned
- 2001-10-16 MX MXPA03003422A patent/MXPA03003422A/es active IP Right Grant
- 2001-10-16 EP EP01983556A patent/EP1366440A2/en not_active Withdrawn
- 2001-10-16 YU YU25603A patent/YU25603A/sh unknown
- 2001-10-16 CA CA002423672A patent/CA2423672A1/en not_active Abandoned
- 2001-10-16 BR BR0114987-3A patent/BR0114987A/pt not_active Application Discontinuation
- 2001-10-16 CZ CZ20031090A patent/CZ20031090A3/cs unknown
- 2001-10-16 IL IL15533201A patent/IL155332A0/xx unknown
- 2001-10-16 PL PL01364772A patent/PL364772A1/xx not_active Application Discontinuation
- 2001-10-16 WO PCT/EP2001/011955 patent/WO2002033596A2/en active Application Filing
- 2001-10-16 SK SK468-2003A patent/SK4682003A3/sk not_active Application Discontinuation
- 2001-10-16 AU AU1502802A patent/AU1502802A/xx active Pending
- 2001-10-16 CN CNB018207227A patent/CN1264110C/zh not_active Expired - Fee Related
- 2001-10-16 UA UA2003043420A patent/UA79231C2/uk unknown
- 2001-10-16 JP JP2002536914A patent/JP2004512603A/ja not_active Withdrawn
-
2003
- 2003-03-31 HR HR20030240A patent/HRP20030240A2/hr not_active Application Discontinuation
- 2003-04-10 BG BG107717A patent/BG107717A/bg unknown
- 2003-04-14 NO NO20031730A patent/NO20031730D0/no not_active Application Discontinuation
-
2004
- 2004-07-08 HK HK04104959A patent/HK1061911A1/xx not_active IP Right Cessation
-
2006
- 2006-12-04 JP JP2006327405A patent/JP2007137887A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NO20031730L (no) | 2003-04-14 |
| CN1493051A (zh) | 2004-04-28 |
| US20040083060A1 (en) | 2004-04-29 |
| NO20031730D0 (no) | 2003-04-14 |
| IL155332A0 (en) | 2003-11-23 |
| HK1061911A1 (en) | 2004-10-08 |
| YU25603A (sh) | 2005-07-19 |
| ZA200302395B (en) | 2004-03-29 |
| AU1502802A (en) | 2002-04-29 |
| WO2002033596A3 (en) | 2003-10-02 |
| AU2002215028B2 (en) | 2007-11-15 |
| WO2002033596A2 (en) | 2002-04-25 |
| BR0114987A (pt) | 2004-02-03 |
| SK4682003A3 (en) | 2003-12-02 |
| CA2423672A1 (en) | 2002-04-25 |
| MXPA03003422A (es) | 2004-05-04 |
| KR20030059196A (ko) | 2003-07-07 |
| CN1264110C (zh) | 2006-07-12 |
| BG107717A (bg) | 2004-01-30 |
| EP1366440A2 (en) | 2003-12-03 |
| PL364772A1 (en) | 2004-12-13 |
| CZ20031090A3 (cs) | 2004-01-14 |
| EE200300150A (et) | 2003-08-15 |
| HRP20030240A2 (en) | 2005-02-28 |
| HUP0302507A3 (en) | 2004-05-28 |
| EA200300475A1 (ru) | 2003-10-30 |
| JP2004512603A (ja) | 2004-04-22 |
| JP2007137887A (ja) | 2007-06-07 |
| HUP0302507A2 (hu) | 2003-11-28 |
| EA005286B1 (ru) | 2004-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA79231C2 (en) | Method for a discrete substructural analysis and a computer system for realizing the same | |
| Korb et al. | PLANTS: Application of ant colony optimization to structure-based drug design | |
| Fiser | Comparative protein structure modelling | |
| AU2002215028A1 (en) | Method of operating a computer system to perform a discrete substructural analysis | |
| US6230102B1 (en) | Computer system and process for identifying a charge distribution which minimizes electrostatic contribution to binding at binding between a ligand and a molecule in a solvent and uses thereof | |
| Osakwe et al. | The significance of discovery screening and structure optimization studies | |
| Skjærven et al. | Accounting for conformational variability in protein–ligand docking with NMR-guided rescoring | |
| Yang et al. | Chemical-protein interactome and its application in off-target identification | |
| Stultz et al. | Predicting protein structure with probabilistic models | |
| Nicolotti et al. | Improving quantitative structure− activity relationships through multiobjective optimization | |
| US20020025535A1 (en) | Prioritization of combinatorial library screening | |
| Sprague et al. | CATALYST pharmacophore models and their utility as queries for searching 3D databases | |
| WO2004081841A1 (en) | Computational protein probing to identify binding sites | |
| US20030228624A1 (en) | Molecular docking methods for assessing complementarity of combinatorial libraries to biotargets | |
| Hiss et al. | Combinatorial chemistry by ant colony optimization | |
| CA2477459C (en) | Comparative field analysis (comfa) utilizing topomeric alignment of molecular fragments | |
| US20140171332A1 (en) | System for the efficient discovery of new therapeutic drugs | |
| Wu | Development and application of CDOCKER docking methodology | |
| Piparo et al. | Bisphenol A binding promiscuity: a virtual journey through the universe of proteins | |
| Devi et al. | Community Benchmarking Exercises for Docking and Scoring | |
| Fiser | Comparative protein structure modelling | |
| Bradshaw | Proteomics today, proteomics tomorrow | |
| Elofsson et al. | Towards a structurally resolved human protein interaction network | |
| WO2005114458A1 (en) | Computational protein probing to identify binding sites | |
| CA2488411A1 (en) | Process for identifying similar 3d substructures onto 3d atomic structures and its applications |